Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VRTX – Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorpor
VRTX
$444.40
Name : Vertex Pharmaceuticals Incorpor
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $114,120,581,120.00
EPSttm : -3.84
finviz dynamic chart for VRTX
Vertex Pharmaceuticals Incorpor
$444.40
0.70%
$3.10

Float Short %

1.58

Margin Of Safety %

Put/Call OI Ratio

0.62

EPS Next Q Diff

0.54

EPS Last/This Y

20.08

EPS This/Next Y

2.65

Price

441.19

Target Price

507.67

Analyst Recom

2.06

Performance Q

-12.19

Relative Volume

2.13

Beta

0.41

Ticker: VRTX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02VRTX445.370.670.5048548
2025-06-03VRTX446.640.660.5349272
2025-06-04VRTX445.90.660.4549430
2025-06-05VRTX443.750.660.7649741
2025-06-06VRTX450.490.670.4250173
2025-06-09VRTX445.50.660.8449057
2025-06-10VRTX451.690.660.5149810
2025-06-11VRTX452.760.660.5650307
2025-06-12VRTX460.060.670.3050497
2025-06-13VRTX455.70.660.6850851
2025-06-16VRTX450.780.651.2949195
2025-06-17VRTX442.010.660.7650049
2025-06-18VRTX448.610.650.0650291
2025-06-20VRTX440.970.660.7750234
2025-06-23VRTX443.60.630.4836366
2025-06-24VRTX450.270.630.2537153
2025-06-25VRTX445.830.620.3038220
2025-06-26VRTX443.450.611.5138669
2025-06-27VRTX441.120.620.6239437
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02VRTX445.32133.45444.518.00
2025-06-03VRTX446.48133.45417.618.00
2025-06-04VRTX446.05133.45399.818.00
2025-06-05VRTX443.82133.45380.718.00
2025-06-06VRTX450.39133.45495.218.00
2025-06-09VRTX446.15133.45364.318.00
2025-06-10VRTX451.56133.45480.918.00
2025-06-11VRTX452.58133.45428.618.00
2025-06-12VRTX460.06133.45506.118.00
2025-06-13VRTX455.60133.45364.218.00
2025-06-16VRTX450.85133.45362.018.00
2025-06-17VRTX442.00133.45310.318.00
2025-06-18VRTX448.40133.45493.618.00
2025-06-20VRTX440.87133.45326.118.00
2025-06-23VRTX443.47133.45447.618.00
2025-06-24VRTX450.23133.35496.717.83
2025-06-25VRTX445.80133.35362.917.83
2025-06-26VRTX443.31133.35386.118.00
2025-06-27VRTX441.19133.35389.318.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02VRTX-4.746.321.88
2025-06-03VRTX-4.746.321.88
2025-06-04VRTX-4.746.321.88
2025-06-05VRTX-4.746.321.88
2025-06-06VRTX-4.746.321.88
2025-06-09VRTX-4.746.331.88
2025-06-10VRTX-4.746.331.88
2025-06-11VRTX-4.746.331.72
2025-06-12VRTX-4.746.331.72
2025-06-13VRTX-4.746.331.72
2025-06-16VRTX-4.746.831.72
2025-06-18VRTX-4.746.831.72
2025-06-20VRTX-4.746.831.72
2025-06-23VRTX-4.746.901.72
2025-06-24VRTX-4.746.901.72
2025-06-25VRTX-4.746.901.72
2025-06-26VRTX-4.746.901.58
2025-06-27VRTX-4.746.901.58
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

4.06

Avg. EPS Est. Current Quarter

4.28

Avg. EPS Est. Next Quarter

4.6

Insider Transactions

-4.74

Institutional Transactions

6.9

Beta

0.41

Average Sales Estimate Current Quarter

2902

Average Sales Estimate Next Quarter

3034

Fair Value

Quality Score

57

Growth Score

47

Sentiment Score

57

Actual DrawDown %

15.1

Max Drawdown 5-Year %

-41.6

Target Price

507.67

P/E

Forward P/E

21.22

PEG

P/S

10.26

P/B

6.87

P/Free Cash Flow

EPS

-3.92

Average EPS Est. Cur. Y​

18

EPS Next Y. (Est.)

20.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-8.95

Relative Volume

2.13

Return on Equity vs Sector %

-29.9

Return on Equity vs Industry %

-12

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

5389.3
Vertex Pharmaceuticals Incorpor
Sector: Healthcare
Industry: Biotechnology
Employees: 6100
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
stock quote shares VRTX – Vertex Pharmaceuticals Incorporated Stock Price stock today
news today VRTX – Vertex Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch VRTX – Vertex Pharmaceuticals Incorporated yahoo finance google finance
stock history VRTX – Vertex Pharmaceuticals Incorporated invest stock market
stock prices VRTX premarket after hours
ticker VRTX fair value insiders trading